| Literature DB >> 36268277 |
Yanfei Jia1, Wentao Wu1, Youchao Xiao1, Kefan Cai1, Songbai Gui1, Qiang Li2, Tian Li3.
Abstract
Background: Craniopharyngioma (CP) is a benign slow-growing tumor. It tends to affect children, and the number of patients is on rise. Considering the high morbidity and mortality of CP, it is urgent and pivotal to identify new biomarkers to uncover the etiology and pathogenesis of CP.Entities:
Year: 2022 PMID: 36268277 PMCID: PMC9578790 DOI: 10.1155/2022/6891655
Source DB: PubMed Journal: J Oncol ISSN: 1687-8450 Impact factor: 4.501
Figure 1Heatmap and volcano plot of DEGs. (a) Heatmap of the differently expressed genes according to the values of |logFC| > 2. (b) Volcano map of differently expressed genes between CP tissues and normal pituitary tissues.
Gene ontology analysis for aberrant differentially expressed genes in craniopharyngioma.
| Category | Term | Count | % |
|
|---|---|---|---|---|
| Low expression | ||||
| GOTERM_BP_DIRECT | GO:1902018 ~ negative regulation of cilium assembly | 2 | 3.64 | 0.01697 |
| GOTERM_BP_DIRECT | GO:0072577 ~ endothelial cell apoptotic process | 2 | 3.64 | 0.01697 |
| GOTERM_BP_DIRECT | GO:0006355 ~ regulation of transcription, DNA-templated | 9 | 16.36 | 0.02695 |
| GOTERM_BP_DIRECT | GO:0070588 ~ calcium ion transmembrane transport | 3 | 5.45 | 0.034121 |
| GOTERM_BP_DIRECT | GO:0042462 ~ eye photoreceptor cell development | 2 | 3.64 | 0.043071 |
| High expression | ||||
| GOTERM_CC_DIRECT | GO:0005925 ~ focal adhesion | 30 | 9.35 | 5.60 |
| GOTERM_CC_DIRECT | GO:0070062 ~ extracellular exosome | 90 | 28.12 | 2.77 |
| GOTERM_CC_DIRECT | GO:0009986 ~ cell surface | 28 | 8.75 | 1.64 |
| GOTERM_CC_DIRECT | GO:0005615 ~ extracellular space | 46 | 14.35 | 1.51 |
| GOTERM_CC_DIRECT | GO:0031012 ~ extracellular matrix | 18 | 5.63 | 5.44 |
| GOTERM_BP_DIRECT | GO:0007155 ~ cell adhesion | 28 | 8.75 | 1.07 |
| GOTERM_BP_DIRECT | GO:0030198 ~ extracellular matrix organization | 17 | 5.31 | 1.58 |
| GOTERM_BP_DIRECT | GO:0016337 ~ single organismal cell-cell adhesion | 9 | 2.81 | 2.60 |
| GOTERM_BP_DIRECT | GO:0071404 ~ cellular response to low-density lipoprotein particle stimulus | 4 | 1.25 | 3.43 |
| GOTERM_BP_DIRECT | GO:0042060 ~ wound healing | 8 | 2.50 | 3.43 |
| GOTERM_MF_DIRECT | GO:0050839 ~ cell adhesion molecule binding | 8 | 2.50 | 5.23 |
| GOTERM_MF_DIRECT | GO:0001948 ~ glycoprotein binding | 8 | 2.50 | 7.12 |
| GOTERM_MF_DIRECT | GO:0004871 ~ signal transducer activity | 13 | 4.06 | 9.79 |
| GOTERM_MF_DIRECT | GO:0098641 ~ cadherin binding involved in cell-cell adhesion | 15 | 4.69 | 2.15 |
| GOTERM_MF_DIRECT | GO:0005515 ~ protein binding | 166 | 51.88 | 5.92 |
Results of KEGG enrichment for the differentially expressed genes.
| Category | Term | Count | % |
| Genes |
|---|---|---|---|---|---|
| Low expression | |||||
| KEGG_PATHWAY | hsa04972: pancreatic secretion | 3 | 5.454545 | 0.009187 | CEL, ATP2B3, GNAS |
| KEGG_PATHWAY | hsa04261: adrenergic signaling in cardiomyocytes | 3 | 5.454545 | 0.019518 | ATP2B3, CACNB2, GNAS |
| High expression | |||||
| KEGG_PATHWAY | hsa05200: pathways in cancer | 18 | 5.625 | 1.66 | PTGER3, PTGS2, ERBB2, CDH1, GLI3, MMP2, CTNNB1, JUP, MAPK1, CBLC, ITGA6, RAC2, JUN, SLC2A1, RAC1, LAMC1, HHIP, FGF1 |
| KEGG_PATHWAY | hsa04510: focal adhesion | 14 | 4.375 | 2.41 | ERBB2, TNC, ITGB5, FLNA, MYL9, CTNNB1, MAPK1, ITGA6, RAC2, JUN, RAC1, LAMC1, SPP1, PARVA |
| KEGG_PATHWAY | hsa05205: proteoglycans in cancer | 13 | 4.0625 | 8.27 | LUM, ERBB2, ITGB5, TLR4, MMP2, FLNA, CTNNB1, CBLC, MAPK1, SDC1, CD44, RAC1, MSN |
| KEGG_PATHWAY | hsa04151: PI3K-Akt signaling pathway | 12 | 3.75 | 0.022876 | MAPK1, SGK1, YWHAZ, ITGA6, TNC, RAC1, YWHAB, ITGB5, TLR4, LAMC1, FGF1, SPP1 |
| KEGG_PATHWAY | hsa04810: regulation of actin cytoskeleton | 11 | 3.4375 | 0.001989 | MAPK1, ENAH, ITGA6, RAC2, CHRM3, RAC1, ITGB5, ITGB2, MSN, FGF1, MYL9 |
| KEGG_PATHWAY | hsa05412: arrhythmogenic right ventricular cardiomyopathy (ARVC) | 8 | 2.5 | 9.23E-05 | JUP, ITGA6, DSG2, ITGB5, GJA1, DSP, CACNA2D3, CTNNB1 |
The six clusters obtained from module analysis using MCODE.
| Cluster | Score (density∗#nodes) | Nodes | Edges | Node IDs |
|---|---|---|---|---|
| 1 | 6 | 9 | 24 | CCL5, PPBP, APLNR, ANXA1, GPR65, F2RL1, PTGER3, CHRM3, APP |
| 2 | 5 | 5 | 10 | GBP6, HLA-DPA1, HLA-DPB1, CD44, IRF6 |
| 3 | 4.5 | 5 | 9 | TOP2A, ENTPD3, RRM1, TYMS, RRM2 |
| 4 | 4 | 4 | 6 | XYLT1, BGN, SDC1, CSPG4 |
| 5 | 3 | 3 | 3 | LRRFIP1, FGF1, ERLIN2 |
| 6 | 3 | 3 | 3 | ITGA6, YWHAB, YWHAZ |
Figure 2Cluster analysis of the PPI network. Three-hundred and differently eighty-four expressed genes were filtered into the DEGs' PPI network complex.
Figure 3WGCNA for the GSE94349 and GSE26966 datasets. (a) The top image shows a gene dendrogram, and the bottom image shows the gene modules with different colors. (b) Correlation between modules and traits. The upper number in each cell refers to the correlation coefficient of each module in the trait, and the lower number is the corresponding p value. Among them, the turquoise modules were the most relevant modules with cancer traits. (c) A heatmap of 1,000 genes was selected at random. The intensity of the red color indicates the strength of the correlation between pairs of modules on a linear scale. (d) A scatter plot of CP tissues and normal pituitary tissues in the turquoise module. Intramodular analysis of the genes found in the turquoise module, which contains genes that have a high correlation with cervical cancer, with p < 1e − 200 and correlation = 0.99.
Figure 4The key intersecting genes obtained from Venn diagram of DEGs and verified by Western blot. (a) A Venn diagram of DEGs and hub genes in the turquoise module shows 4 key intersecting genes. (b) Results verified by Western blot and obtained from the selected 8 samples. Abbreviations: C1-C4: craniopharyngioma tissues No.1-No.4; P1-P4: pituitary tissues No.1-No.4.
Figure 5Grayscale value analysis for Western blotting. PPBP (CXCL7), CD44, SDC1, and ITGA6 (CD49f) protein levels are shown for the craniopharyngioma tissues and pituitary tissues. ∗p value < 0.05.
Figure 6Survival analysis according to the levels of CD44, SDC1, PPBP, and ITGA6 expressions. (a) Effects of CD44 expression on craniopharyngioma patient survival. (b) Effects of SDC1 expression on craniopharyngioma patient survival. (c) Effects of PPBP expression on craniopharyngioma patient survival. (d) Effects of ITGA6 expression on craniopharyngioma patient survival.